Krystal Biotech (KRYS) – Research Analysts’ Recent Ratings Changes

by · The Cerbat Gem

Krystal Biotech (NASDAQ: KRYS) has recently received a number of price target changes and ratings updates:

  • 5/7/2025 – Krystal Biotech had its price target lowered by analysts at Guggenheim from $195.00 to $189.00. They now have a “buy” rating on the stock.
  • 5/7/2025 – Krystal Biotech had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $219.00 price target on the stock.
  • 5/6/2025 – Krystal Biotech had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $240.00 price target on the stock.
  • 4/28/2025 – Krystal Biotech had its price target raised by analysts at HC Wainwright from $221.00 to $240.00. They now have a “buy” rating on the stock.

Krystal Biotech Stock Performance

NASDAQ KRYS traded up $7.25 on Monday, hitting $139.43. 335,706 shares of the stock were exchanged, compared to its average volume of 300,548. The stock has a fifty day moving average price of $171.56 and a two-hundred day moving average price of $170.01. The firm has a market capitalization of $4.03 billion, a P/E ratio of 46.63 and a beta of 0.79. Krystal Biotech, Inc. has a 52-week low of $131.05 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $88.18 million for the quarter, compared to analysts’ expectations of $98.66 million. Sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. This represents a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This represents a 5.62% decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is owned by company insiders.

Institutional Trading of Krystal Biotech

Hedge funds have recently bought and sold shares of the stock. FMR LLC lifted its position in shares of Krystal Biotech by 0.5% during the fourth quarter. FMR LLC now owns 4,314,014 shares of the company’s stock valued at $675,833,000 after buying an additional 21,133 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Krystal Biotech by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock valued at $450,938,000 after purchasing an additional 28,707 shares during the last quarter. Avoro Capital Advisors LLC lifted its holdings in shares of Krystal Biotech by 0.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company’s stock valued at $411,831,000 after purchasing an additional 6,600 shares during the last quarter. Hood River Capital Management LLC lifted its holdings in shares of Krystal Biotech by 2.1% during the 4th quarter. Hood River Capital Management LLC now owns 512,726 shares of the company’s stock valued at $80,324,000 after purchasing an additional 10,622 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Krystal Biotech by 16.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company’s stock valued at $79,812,000 after purchasing an additional 71,200 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Read More